Akeso reports phase 3 overall survival win for ivonescimab in advanced biliary tract cancer
Akeso announced that its bispecific antibody ivonescimab combined with chemotherapy improved overall survival in a China phase 3 trial for advanced biliary tract cancer, beating the standard regimen of AstraZeneca's Imfinzi plus chemo.
The Harmoni-GI1 study met its primary endpoint of overall survival as well as key secondary endpoints of progression-free survival and objective response rate, which the company described as clinically meaningful and statistically significant.
CEO Michelle Xia highlighted that this is the first successful late-stage trial of ivonescimab outside non-small cell lung cancer, underscoring the drug's broader potential, while also defending the data against ongoing skepticism about its performance in lung cancer.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that